Genzyme Sues Sarepta Over Viral Vector Patent Infringement

The Sanofi subsidiary Genzyme is suing gene therapy firm Sarepta, alleging that Elevidys, an authorised medicine, violates two of its active patents related to the production of viral vectors. According to Genzyme, the patents include formulations and associated techniques that keep viral vector particles liquid and avoid clumping while being manufactured. June 1, 2025 is the day on which both patents expire. The complaint names Catalent, Sarepta's contract manufacturer, although it does not include Catalent as a defendant.

The business is requesting damages and a jury trial. Judge Richard Andrews of the U.S. District Court dismissed Regenxbio and the University of Pennsylvania's lawsuit against Sarepta in January, finding that the patents they claimed were violated were invalid. Sarepta and Catalent are the targets of another lawsuit brought by Regenxbio and Penn. Elevidys, which was authorised in June, launched well and made $334 million in sales in the first quarter of this year.